Details:
Adults hospitalized for acute heart failure were 36% more likely to experience a clinical benefit over 90 days if initiated on Jardiance® (empagliflozin) following stabilization and prior to discharge compared with placebo in the phase III EMPULSE trial.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022